Jackie Collins

Articles

Second-Line Axi-Cel Offers a “Practice-Changing” Indication for LBCL

May 3rd 2022

Lori A. Leslie, MD, reviews how the approval of axicabtagene ciloleucel may impact or enhance current practice patterns for adult patients with large B-cell lymphoma.

Tebentafusp Offers Path Forward in the Uveal Melanoma Treatment Landscape

April 19th 2022

Marlana M. Orloff, MD, overviews how pivotal efficacy and safety data of tebentafusp will improve the treatment paradigm for adult patients with HLA-A*02:01–positive unresectable or metastatic uveal melanoma.

Pembrolizumab Plus Chemotherapy Elicits Meaningful pCR for Gastric, GEJ Adenocarcinoma

April 11th 2022

Perioperative pembrolizumab plus standard of care chemotherapy followed by adjuvant pembrolizumab showed a meaningful pathological complete response rate in patients with resectable gastric and gastroesophageal junction adenocarcinoma.

Olaparib Combination Shows Notable Non-Progression Rate in Endometrial Cancer

April 11th 2022

In the ENDOLA trial, olaparib in combination with metronomic cyclophosphamide and metformin showed a significant non-progression rate in patients with recurrent advanced or metastatic endometrial cancer.

Pacritinib Paves a “Unique Lane” of Treatment for Select Myelofibrosis

April 5th 2022

Patients who develop post–essential thrombocythemia myelofibrosis or post–polycythemia vera myelofibrosis, which are associated with significant symptom burden and bone marrow failure, have limited therapies available for effective treatment.

Transplants Are in His Blood: Richard J. O'Reilly Is a Giant of Cancer Care in Pediatric Cancer

April 4th 2022

“I can’t conceive of anything worse than being in a situation where you can’t ask, ‘How do we get better?’ ”

Marshall Highlights the Importance of Distinct Approaches to GI Cancers

April 1st 2022

Distinctions in histology, molecular profiles, and tumor location have set diverging course of care for the treatment of patients with gastrointestinal cancers.

Investigators Assess Benefit of Adjuvant Pembrolizumab Plus Chemotherapy Combinations in High-Risk Endometrial Cancer

March 18th 2022

The durable antitumor activity of pembrolizumab and the clinically beneficial outcomes demonstrated with both adjuvant chemotherapy and adjuvant chemoradiotherapy have provided investigators with the foundation to assess the 2 approaches in combination in a phase 3 study.

Neoadjuvant Chemotherapy Benefit Retains Stronghold for Patients With MIBC, UTUC

March 15th 2022

Effective treatment paths leveraging neoadjuvant chemotherapy have been well-established for patients with muscle-invasive bladder cancer, with mounting retrospective and prospective data continuing to demonstrate overall survival benefit compared with adjuvant chemotherapy.

Investigators Look to Enhance Outcomes for Unresectable ESCC With Chemoradiation Combination

March 10th 2022

Since most diagnoses of esophageal squamous cell carcinoma are made when the disease is in advanced stages, investigators have initiated studies to evaluate the efficacy of immunotherapy in earlier lines of therapy, including in combination with chemoradiotherapy.

Loprinzi Shares Top Concerns, Best Practices for Treatment-Related Toxicity Management in Breast Cancer

March 4th 2022

Charles L. Loprinzi, MD, discusses some of the most common treatment-related toxicities in breast cancer and provided insight into various current and investigational approaches available to patients.

Superior Health-Related QOL Outcomes With Nivolumab/Cabozantinib Endure in RCC

February 19th 2022

At a nearly 3-year median follow-up, health-related quality-of-life scores were improved or maintained over time among patients with advanced renal cell carcinoma who received with nivolumab plus cabozantinib compared with those who received sunitinib.

2021 Approvals Expand Access to Care for Patients Across Tumor Types

February 4th 2022

In 2021, 13 novel agents were approved across hematology/oncology. Additionally, there were many other notable approvals—whether they were new formulations, expanded indications, or biosimilar approvals—across tumor types that expanded accessibility for varying patient populations.

Subcutaneous Daratumumab Plus Kd Is a “Gamechanger” for Patients With Multiple Myeloma

January 24th 2022

Ajai Chari, MD, reviews the takeaways from the PLEIADES trial and its comparability with the CANDOR trial, and how a subcutaneous formulation of a daratumumab combination became a pivotal player in the treatment enhancement for patients with relapsed or refractory multiple myeloma.

New, Updated Data Demonstrate Promising Future in Advanced Melanoma

January 14th 2022

Jeffrey S. Weber, MD, PhD, overviews the successes made in the melanoma setting in the past decade and the challenges to overcome in the future.

Pembrolizumab Proves Potential as New Standard of Care for RCC in Adjuvant Setting

December 17th 2021

Pembrolizumab demonstrated a statistically significant and clinically meaningful improvement in disease-free survival vs placebo as a postnephrectomy adjuvant therapy in patients with renal cell carcinoma at intermediate-high or high risk of recurrence, and in those who are M1 with no evidence of disease.

Mobocertinib Provides Treatment Option for EGFR Exon 20–Mutant NSCLC

November 20th 2021

Joel Neal, MD, PhD, discusses the evolving treatment landscape for patients with EGFR exon 20–mutant non–small cell lung cancer.

Sullivan Unpacks Breakthroughs, Challenges in the Treatment of Advanced Melanoma

November 8th 2021

The addition of immune checkpoint inhibitors and targeted therapies has paved the way for advances in the adjuvant and met-astatic setting with recent data from clinical trials demonstrating significant improvements in overall survival for patients with advanced melanoma.

Sacituzumab Govitecan May Be New Standard of Care in Metastatic TNBC

October 19th 2021

Hope S. Rugo, MD, FASCO, provides her insights on the final analysis data from the international phase 3 ASCENT trial.

Liso-cel Plus Ibrutinib Demonstrates Tolerable Safety Profile in Relapsed/Refractory CLL/SLL

September 19th 2021

Lisocabtagene maraleucel in combination with ibrutinib was associated with manageable safety for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, according to updated data from the phase 1 TRANSCEND-CLL-004 trial.